ONCBeiGeneFinished
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 370 (final count)
- Started
- Jun 11, 2019
- Main results expected
- Jan 8, 2025
- Fully finished
- Mar 31, 2025
- Results posted
- Apr 13, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03957590 · record last updated 2026-04-13 · checked 2026-11-09 15:47 UTC